POINT OF CARE DIAGNOSTICS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates the global point of care diagnostics market with an estimated market share of 40.3% in 2024. With the presence of major players like Abbott, BD, Roche and several startups, the U.S. accounts for over 45% of the entire market. The region enjoys various advantages such as an expanding geriatric population prone to chronic diseases, widespread adoption of decentralized healthcare models, and favorable reimbursement policies promoting home-based testing. North America has a highly developed pharmaceutical industry contributing to continued innovation in technologies and products. Due to supportive regulatory environment under the U.S. FDA, medical devices and diagnostic kits face faster clearance pathway, ensuring companies recover R&D investments swiftly.

Asia Pacific has emerged as the fastest growing market for point of care testing diagnostics. Countries like China, India, Japan and South Korea are industrializing healthcare at an unprecedented rate. Favorable policies around medical tourism and public-private investments have accelerated infrastructure growth. China has invested for strengthening primary care delivery outside major hospitals. This emphasis on community-level testing coupled with rising affluence has boosted demand. Regional frontrunners like Sansure Biotech from China are expanding globally through acquisitions and partnerships. These offer low-cost alternatives to Western competitors. Growing prevalence of non-communicable diseases can also drive the market growth. Due to its massive population and government momentum around universal health coverage, Asia Pacific is primed to overtake other regions in the long run.